The approval of sorafenib, together with the approval of second-generation RAF inhibitors vemurafenib and dabrafenib which act on cancers harboring BRAF mutations, has sparked interest in the discovery of new molecules selectively targeting this pathway (see References [76,77] for reviews covering RAF signaling and inhibition in cancer). Here, BRAF is linked to cancer.